secwatch.observer — SEC 8-K summary
======================================

Issuer:     ArriVent BioPharma, Inc. (AVBP)
CIK:        0001868279
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001558370-25-010974
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ArriVent Q2 2025 net loss $95.8M; firmonertinib PACC data positive; ADC ARR-217 dosed
--------------------------------------------------------------------------------

- Cash and investments $254.5M at June 30, plus $81.1M raised in July 2025 public offering; runway extended to mid-2027.
- Net loss $95.8M for H1 2025 vs. $39.3M in H1 2024; R&D expense $89.0M including $40M one-time upfront to Lepu BioPharma.
- Positive interim Phase 1b data for firmonertinib in EGFR PACC mutant NSCLC; final data at WCLC September 2025.
- First patient dosed in Phase 1 for ARR-217 (CDH17-targeted ADC) in gastrointestinal tumors by partner Lepu.
- Top-line firmonertinib data from FURVENT Phase 3 for EGFR Exon20 insertion expected early 2026; PACC Phase 3 ALPACCA enrollment in 2H 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1868279/000155837025010974/0001558370-25-010974-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1868279/000155837025010974/avbp-20250811x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-010974

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer